PCRX Quote, Financials, Valuation and Earnings

Intra-Cellular Therapies has a net margin of -85.11% compared to Pacira BioSciences's net margin of -15.03%. Pacira BioSciences's return on equity of -10.74% beat Intra-Cellular Therapies's return on equity of -10.58%.

Pacira BioSciences has a consensus price target of $19.29, signalling downside risk potential of -6.56%. On the other hand Intra-Cellular Therapies has an analysts' consensus of $103.21 which suggests that it could grow by 8.8%. Given that Intra-Cellular Therapies has higher upside potential than Pacira BioSciences, analysts believe Intra-Cellular Therapies is more attractive than Pacira BioSciences.

Pacira BioSciences has a beta of 0.765, which suggesting that the stock is 23.508% less volatile than S&P 500. In comparison Intra-Cellular Therapies has a beta of 0.704, suggesting its less volatile than the S&P 500 by 29.611%.

Pacira BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intra-Cellular Therapies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira BioSciences pays -- of its earnings as a dividend. Intra-Cellular Therapies pays out -- of its earnings as a dividend.

Pacira BioSciences quarterly revenues are $168.6M, which are smaller than Intra-Cellular Therapies quarterly revenues of $175.2M. Pacira BioSciences's net income of -$143.5M is lower than Intra-Cellular Therapies's net income of -$26.3M. Notably, Pacira BioSciences's price-to-earnings ratio is 11.70x while Intra-Cellular Therapies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira BioSciences is 1.62x versus 15.58x for Intra-Cellular Therapies. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -85.11% compared to Pacira BioSciences's net margin of 8.48%. Pacira BioSciences's return on equity of -10.74% beat Eli Lilly and's return on equity of 66.4%.

Pacira BioSciences has a consensus price target of $19.29, signalling downside risk potential of -6.56%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 23.02%. Given that Eli Lilly and has higher upside potential than Pacira BioSciences, analysts believe Eli Lilly and is more attractive than Pacira BioSciences.

Pacira BioSciences has a beta of 0.765, which suggesting that the stock is 23.508% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.729%.

Pacira BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.30 per share. Pacira BioSciences pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pacira BioSciences quarterly revenues are $168.6M, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Pacira BioSciences's net income of -$143.5M is lower than Eli Lilly and's net income of $970.3M. Notably, Pacira BioSciences's price-to-earnings ratio is 11.70x while Eli Lilly and's PE ratio is 86.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira BioSciences is 1.62x versus 17.70x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -85.11% compared to Pacira BioSciences's net margin of -49.65%. Pacira BioSciences's return on equity of -10.74% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Pacira BioSciences has a consensus price target of $19.29, signalling downside risk potential of -6.56%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 434.43%. Given that NovaBay Pharmaceuticals has higher upside potential than Pacira BioSciences, analysts believe NovaBay Pharmaceuticals is more attractive than Pacira BioSciences.

Pacira BioSciences has a beta of 0.765, which suggesting that the stock is 23.508% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Pacira BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira BioSciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Pacira BioSciences quarterly revenues are $168.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Pacira BioSciences's net income of -$143.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Pacira BioSciences's price-to-earnings ratio is 11.70x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira BioSciences is 1.62x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -85.11% compared to Pacira BioSciences's net margin of -2357.27%. Pacira BioSciences's return on equity of -10.74% beat Palatin Technologies's return on equity of --.

Pacira BioSciences has a consensus price target of $19.29, signalling downside risk potential of -6.56%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1404.43%. Given that Palatin Technologies has higher upside potential than Pacira BioSciences, analysts believe Palatin Technologies is more attractive than Pacira BioSciences.

Pacira BioSciences has a beta of 0.765, which suggesting that the stock is 23.508% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Pacira BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira BioSciences pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Pacira BioSciences quarterly revenues are $168.6M, which are larger than Palatin Technologies quarterly revenues of $350K. Pacira BioSciences's net income of -$143.5M is lower than Palatin Technologies's net income of -$7.8M. Notably, Pacira BioSciences's price-to-earnings ratio is 11.70x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira BioSciences is 1.62x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.